Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels.
Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dipeptide Peptidase 4 (DPP-4) Inhibitors volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dipeptide Peptidase 4 (DPP-4) Inhibitors market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Dipeptide Peptidase 4 (DPP-4) Inhibitors in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Dipeptide Peptidase 4 (DPP-4) Inhibitors manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Merck
Eli Lilly
AstraZenica
Boehringer Ingelheim
Takeda Pharmaceutical Company
BMS
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin

Segment by Application
Hospitals
Clinics